SCHEMBL20889276

SCHEMBL20889276

Cn1cc(-c2nc3cnccn3c2NC2CCCCC2)c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SALL4 Q9UJQ4 3/20 0.60
ALOX5 P09917 3/20 0.57
GAA P10253 6/20 0.56
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 4/20 0.56
MAPT P10636 4/20 0.56
HTT P42858 3/20 0.56
XBP1 P17861 1/20 0.56
GFER P55789 2/20 0.55
HPGD P15428 1/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
KMT2A Q03164 2/20 0.55
TP53 P04637 2/20 0.55
CASP1 P29466 2/20 0.55
CASP7 P55210 2/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20889740 0.86 SALL4 (0.58) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889493 0.81 ALOX5 (0.63) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889284 0.79 GAA (0.74) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889675 0.79 ALOX5 (0.63) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889738 0.79 SALL4 (0.61) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889683 0.79 SALL4 (0.59) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889742 0.76 ALOX5 (0.67) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889319 0.76 GAA (0.75) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889529 0.76 GAA (0.69) SALL4ALOX5GAAALDH1A1KDM4E
SCHEMBL20889477 0.76 ALOX5 (0.73) SALL4ALOX5GAAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed
WO-2019070943-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 SALL4 1/4885ALOX5 3823/4885GAA 3761/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 SALL4 1/4885ALOX5 3823/4885GAA 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.